- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cleveland Clinic Reaches Milestones in Heart Transplantation and Lung Transplantation
In July, Cleveland Clinic completed their 2000th heart and 2000th lung transplantations as the third program in the country to reach this landmark
In July, Cleveland Clinic completed their 2000th heart and 2000th lung transplantations as the third program in the country to reach this landmark. Cleveland Clinic is one of the largest heart transplant programs in the country with survival outcomes higher than the national average. (SRTR Data: Adult 1 yr survival: 97% {national avg 91%} and 3 yr survival: 88% {national avg 85%} Peds: 3 yr survival: 95% {national avg 89%})
Cleveland Clinic began innovative work on heart transplants in 1968, with the official beginning of the program in 1984. On average, Cleveland Clinic performs 50 to 60 transplants per year, including between 5 to 8 pediatric transplants per year. In 1998, a record-breaking year for the program, 113 patients were transplanted, including 8 pediatric patients.
Employers Shift to Equity-Focused Strategies as Health Costs Outpace Wages
October 31st 2024As health care costs escalate, a new survey reveals that 74% of employers are grappling with the impact on employee wages and benefits, with many anticipating further cost-shifting to their workforce.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
